Release date: 27 May 2019
Promoter – Financial Intermediary
NANOBIOTIX SALocation
Description
The project consists of the financing of the borrower's planned expenditures in research, development and innovation (RDI). The RDI expenditure programme will finance all activities required to bring NBTXR3 - a nanoparticle radio-enhancer product - to the market, including the design and conduct of clinical trials. The development programme primarily targets indications in soft tissue sarcomas, head and neck tumours and other solid tumours.
Objectives
The proposed transaction will support research and development (R&D) investments that are required to move forward the promoter's product in the pipeline and bring the products to market.
Sector(s)
- Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 40 million
Total cost (Approximate amount)
EUR 95 million
Environmental aspects
The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Procurement
The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Status
Signed - 26/07/2018
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).